Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

NCT01118039 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer

Interventions

DRUG: sunitinib malate
OTHER: immunohistochemistry staining method
OTHER: laboratory biomarker analysis
OTHER: pharmacological study
PROCEDURE: quality-of-life assessment

Sponsor

Hospital del Mar